Semaglutide shows promise in reducing tobacco use disorder-related health encounters in patients with type 2 diabetes, but further clinical trials are needed to confirm its efficacy.
Novo Nordisk looks beyond weight loss and diabetes to expand in new illnesses
As Novo Nordisk hauls in huge sales from its popular GLP-1 products, the company is thinking about a future beyond obesity and diabetes. During a